]11[]21[
135733
‫שיטת החפיה‬
]54[
ENCAPSULATION METHOD
]22[
]31[
]51[
]71[
]87[
]74[
24.09.1998
9703874-9
]32[ 23.10.1997
]33[ SE
Int. Cl.7 A61K 009/00, 009/14, 009/50, B01J 013/00
JAGOTEC AG, SWITZERLAND
WO/1999/020253
EITAN, PEARL, LATZER AND
,‫ לצר וכהן צדק‬,‫ פרל‬,‫איתן‬
COHEN ZEDEK,
‫ הרצליה‬,12688 .‫ד‬.‫ ת‬, 7 ‫רחוב שנקר‬
P.O.B. 12688
HERZLIYA 46733
[57] A method of encapsulating an active
substance in a biodegradable polymer,
which comprises:
(a) dissolving said biodegradable polymer
in an organic solvent thereof;
(b1) dispersing said active substance in the
organic solution obtained in step (a), to
provide a dispersion with the active
substance as the inner phase thereof, or
alternatively
(b2) emulsifying said active substance,
dissolved in water or other aqueous solvent
therefor, in the organic solution obtained in
step (a), to provide an emulsion with the
active substance as the inner aqueous
phase thereof; and
(c) subjecting the dispersion obtained in
step (b1), or alternatively the emulsion
obtained in step (b2), to an encapsulation
operation with an aqueous polyethylene
glycol solution as a continuous phase, such
that micro or nanoparticles having the
active substance encapsulated therein are
obtained.
__________
]11[]21[
]54[
HIGH SENSOR RESOLUTION
POSITION SENSOR DEVICE
AND METHOD
]22[
]51[
]71[
08.05.2000
Int. Cl.7 G01D 005/244
YASKAWA ESHED TECHNOLOGY
LTD.
YVES VILLARET, SHMUEL
PROKOPETS
EDWARD LANGER,
44-46 MONTEFIORE STREET
TEL AVIV 65201
]72[
]74[
November 20, 2005– ‫י"ח בחשון התשס"ו‬
136016
‫שיטה והתקן לחיישן מיקום ברזולוציה‬
‫גבוהה‬
‫ ראש העין‬,‫יאסקווה אשד טכנולוגיה בע''מ‬
‫ שמואל פרוקופץ‬,‫איב וילרה‬
,‫אדוארד לנגר‬
‫ תל אביב‬,44-46‫מונטיפיורי‬
1956
[57] A sensor device (10) for measuring a
changing variable of a system and
providing output values representing the
system variable with increased resolution,
said device comprising: means (24) for
providing a pulse with each transition of
the measured variable over a level of each
of a set of regularly spaced apart
predetermined levels, means (26) for
generating a train of system clock pulses at
a first rate and a train of divided system
clock pulses at a fraction of said first rate;
first means (30) for counting a first number
of pulses of said divided system clock
pulse train occurring between each
occurrence of said transition pulse;
means (32) for storing said first counted
number of pulses of said divided system
clock pulse train; second means (34) for
counting a second number of pulses of said
divided system clock pulse train, and
resetting said second counted number upon
each transition pulse; second means for
storing said second counted number of
pulses of said divided system clock pulse
train, in a register at a shifted storage
position representing a multiple of said
second counted number of pulses; means
(40) for repeatedly comparing, at a
relatively high rate, said shifted, stored
second counted number and said stored
first counted number and producing a
difference count therebetween if the
former exceeds the latter; means (37) for
generating a high resolution pulse upon
replacing said shifted, stored second
counted number with said difference count
in said register, thus providing several high
resolution pulses between transition
pulses; and
means for calculating the system variable
by counting the number of high resolution
pulses in the interval between occurrences
of said transition pulses.
__________
1957
November 20, 2005– ‫י"ח בחשון התשס"ו‬
]11[]21[
]54[
KIT CONTAINING ESTROGEN
FOR POSTMENOPAUSAL USE
]22[
]31[
]51[
]71[
19.11.1998
975599
]32[ 21.11.1997
Int. Cl.7 A61K 031/57, A61P 005/24
BERLEX LABORATORIES, INC.,
U.S.A.
THE REGENTS OF THE
UNIVERSITY OF CALIFORNIA,
U.S.A.
THE PERMANENTE MEDICAL
GROUP, INC., U.S.A.
KAISER FOUNDATION HEALTH
PLAN, INC., U.S.A.
WO/1999/026631
WOLFF, BREGMAN AND GOLLER,
KEREN HAYESOD ST 19B,
P.O.B. 1352
JERUSALEM 91013
]87[
]74[
[57] A composition for treating a physical
condition resulting from postmenopausal
estrogen decline in a postmenopausal
subject, the composition comprising: an
amount of estrogen which is effective to
produce a serum estradiol level of between
about 5 ph/ml and about 15 pg/ml in the
136175
‫ערכה המכילה אסטרוגן לשמוש לאחר‬
‫הפסקת הוסת‬
]33[
US
,‫ ברגמן וגולר‬,‫וולף‬
‫ ירושלים‬,1352 .‫ד‬.‫ ת‬, '‫ב‬19 ‫רחוב קרן היסוד‬
subject, wherein the physical condition
comprises at least one of postmenopausal
estrogen decline, increased risk of
osteoporotic bone fracture due to
postmenopausal osteoporosis, and loss of
bone mineral density.
__________
November 20, 2005– ‫י"ח בחשון התשס"ו‬
1958
]11[]21[
]54[
PARAMAGNETIC
CARBOHYDRATE REAGENT FOR
TUMOR IMAGING AND /OR
TREATMENT
]22[
]31[
19.11.1998
60/067081
]32[ 20.11.1997
09/195341
18.11.1998
Int. Cl.7 A61K 049/08
DAVID PLATT, U.S.A.
WO/1999/026535
SANFORD T.COLB & CO.,,
P.O.B. 2273,
REHOVOT 76122
]51[
]71[
]87[
]74[
[57] A reagent for magnetic resonance
imaging of a cancerous tumor in vivo
comprising: a carbohydrate which is
capable of binding to or penetrating a
cancerous cell, said carbohydrate having a
136210
‫ריאגנט פחמימתי פאראמגנטי להדמייה‬
‫או טיפול בגידולים‬/‫ו‬
]33[
US
US
,'‫ קולב ושות‬.‫סנפורד ט‬
‫ רחובות‬,2273 .‫ד‬.‫ ת‬, ‫ מרמורק‬,4 ‫שער הגיא‬
paramagnetic atom bonded thereto, said
carbohydrate having an average molecular
weight equal to or less than 2000 daltons;
and a carrier suitable for delivery of said
carbohydrate to the cancerous cell.
__________
]11[]21[
136436
,‫תרכובות המעכבות קולטן מזרחן‬
‫ורכיבים המרכיבים אותם‬,‫הכנתן‬
]54[
PDGF RECEPTOR KINASE
INHIBITOR COMPOUNDS,
THEIR PREPARATION AND
COMPOSITIONS CONTAINING
THEM
]22[
]31[
]51[
]71[
30.11.1998
980596
]32[ 01.12.1997
]33[ US
Int. Cl.7 A61K 031/495, A61P 035/00, C07D 487/02, C07F 015/02
YISSUM RESEARCH
‫יישום חברה לפיתוח המחקר של‬
DEVELOPMENT COMPANY OF
‫ ירושלים‬,‫האוניברסיטה העברית בירושלים‬
THE HEBREW UNIVERSITY OF
JERUSALEM
ALEXANDER LEVITZKI, AVIV
,‫ שמואל בנאי‬,‫ אביב גזית‬,‫אלכסנדר לויצקי‬
GAZIT, SHMUEL BANAI, DAVID
‫ גרשון גולומב‬,‫דוד גרץ‬
GERTZ, GERSHON GOLOMB
WO/1999/028304
G.E. EHRLICH (1995) LTD.,
,‫) בע"מ‬1995( ‫ ארליך‬.‫אי‬.‫ג'י‬
11 MENACHEM BEGIN STREET
‫ רמת גן‬,11‫מנחם בגין‬
RAMAT GAN 52521
]72[
]87[
]74[
1959
November 20, 2005– ‫י"ח בחשון התשס"ו‬
[57] A compound comprising a tyrphostin
of the formula:
wherein R1 and R2 are each independently
selected from the group consisting of alkyl,
alkoxy, halogen, nitro and amine group
and Ar is selected from the group
consisting of phenyl, ferrocene, thiophene,
furane, pyrrole, indole, thiazole, imidazole
and pyridine.
__________
]11[]21[
]54[
SURGICAL CLIP
]22[
]51[
]71[
12.06.2000
Int. Cl.7 A61B 017/122
NITI ALLOYS TECHNOLOGIES
LTD.
LEONID MONASSEVITCH,
SHLOMO LELCUK, MICHAEL
ARAD
JEREMY M. BEN-DAVID & CO.
LTD.,
HAR HOTZVIM HI-TECH PARK,
P.O. B0X 45087 JERUSALEM
]72[
]74[
[57] A surgical clip (10) formed at least
partly of a shape memory alloy, said clip
including: a first length of a wire (12)
defining a closed geometrical shape having
a central opening; a second length of a
wire (22) defining a closed geometrical
shape similar in configuration and
magnitude to that of said first length of
wire, wherein, when placed in side-by-side
registration, said first and second lengths
of wire fully overlap; an intermediate
portion (13) located between said first
length of wire and said second length of
wire, said intermediate portion formed of a
November 20, 2005– ‫י"ח בחשון התשס"ו‬
136702
‫מהדק כירורגי‬
‫ נתניה‬,‫טכנולוגיות סגסוגות ניטי בע"מ‬
‫ מיכאל ארד‬,‫ שלמה ללצ'וק‬,‫לאוניד מונסביץ‬
,‫דוד ושות' בע"מ‬-‫ בן‬.‫ירמיהו מ‬
‫ ירושלים‬,45087 .‫ד‬.‫ ת‬, ‫הר חוצבים‬
shape memory alloy; a cutting element
(48) associated with said first length of
wire; a counter element (26) associated
with said second length of wire and
arranged for cutting engagement with said
cutting element; wherein when at a first
temperature or higher, said first and second
lengths of wire are positioned in a side-byside closed position and said shape
memory alloy is in an elastic state, and
further, when at a second temperature or
lower, below said first temperature, said
shape memory alloy is in a plastic state,
thereby enabling said first and second
1960
lengths of wire to be moved into and to
retain a spaced apart position, and upon
heating of said clip to a temperature at
least equal to said first temperature, said
first and second lengths of wire return to
said side-by-side closed position, thereby
to apply a compressive force to tissue
located therebetween.
__________
]11[]21[
136783
‫תרכובות בנזוקסאזין להגברת תגובה‬
‫ הכנתן ותכשירי רוקחות‬,‫סינפטית‬
‫המכילים אותן‬
]54[
SYNAPTIC RESPONSE
ENHANCING BENZOXAZINE
COMPOUNDS, THEIR
PREPARATION AND
PHARMACEUTICAL
COMPOSITIONS CONTAINING
THEM
]22[
]31[
]51[
]71[
16.12.1998
998300
]32[ 24.12.1997
]33[ US
Int. Cl.7 A61K 031/395, A61P 025/00, C07D 498/04, 498/14, 513/04, 513/14
THE REGENTS OF THE
UNIVERSITY OF CALIFORNIA,
U.S.A.
WO/1999/033469
REINHOLD COHN AND PARTNERS,
,‫ריינהולד כהן ושותפיו‬
21 AHAD HA'AM ST.
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
P.O.BOX 4060,
TEL AVIV 61040
]87[
]74[
[57] A compound of the formula
1961
November 20, 2005– ‫י"ח בחשון התשס"ו‬
wherein:
X1 and X2 are independently selected from
H, NR32,-OR4, and –CH2OR4; or
X1 and X2 taken together are –OCR52O-, OCR52CR52O-, or –OCR5=CR5O-; or
X1 and X2 taken together are –
N=CR6CR6=N-; or
X1 and X2 taken together are –N=CR3NR3; or
X1 and X2 taken together are =N-O-N= or
=N-S-N=; or
X1 and X2 taken together are –O-CR3=N;
Z is O, NR7, and S;
R1 is H, C1-C6 alkyl, or C1-C3 fluoroalkyl,
each occurrence of R2 is independently H,
halogen, cyano, hydroxy, C1-C6 alkoxy,
C1-C3 fluoroalkoxy, mercapto, C1-C6 alkyl,
C1-C3 fluoroalkyl, C2-C6 alkoxyalkyl, C6C12 aryl C3-C12 heteroaryl, C7-C12
arylalkyl, C4-C12 heteroarylalkyl, C6-C12
aryloxy, C7-C12 aryloxyalkyl, C7-C12
arylalkoxy, or C4-C12 heteroarylalkoxy;
each occurrence of R3 and R7 is
independently H, C1-C6 alkyl, C1-C3
fluoroalkyl, C7-C12 arylalkyl or C4-C12
heteroarylalkyl;
each occurrence of R4 is independently H,
C1-C6 alkyl, C1-C3 fluoroalkyl, C2-C6
alkoxyalkyl, C7-C12 arylalkyl, C4-C12
heteroarylalkyl, or C7-C12 aryloxyalkyl;
both R5 are identical, at each occurrence
being H, halogen, cyano, C1-C6 alkyl, C1C3 fluoroalkyl, C2-6 alkoxyalkyl, C7-C12,
arylalkyl, C4-C12 heteroarylalkyl, or C7-C12
aryloxyalkyl; both R6 are identical, at each
occurrence being H, cyano, hydroxy, C1C6 alkoxy, C1-C6 alkyl, C1-C3 fluoroalkyl,
C2-C6 alkoxyalkyl, C7-C12 aryalkyl, C4-C12
heteroarylalkyl, C6-C12 aryloxy, C7-C12
aryloxyalkyl, C7-C12 arylalkoxy, or C4-C12
heteroarylalkoxy and n is 2, 3 or 4.
__________
]11[]21[
November 20, 2005– ‫י"ח בחשון התשס"ו‬
137245
1962
]54[
INTRAOCULAR LENS IMPLANT
WITH TELESCOPE SUPPORT
]22[
]31[
]51[
]71[
05.01.1999
09/007379
]32[ 15.01.1998
Int. Cl.7 A61F 002/16
VISIONCARE OPHTHALMIC
TECHNOLOGIES, INC., U.S.A.
YOSEF GROSS, GIDEON DOTAN,
ISAAC LIPSHITZ
WO/1999/036004
SANFORD T.COLB & CO.,,
P.O.B. 2273,
REHOVOT 76122
]72[
]87[
]74[
[57] An intraocular lens (IOL) implant
(10) for implantation in an eye having a
capsular bag, a posterior chamber and an
anterior chamber, the implant comprising:
a first carrying member (12) adapted to be
attached to said capsular bag; and a
telescope (16) attached to and extending
from said first carrying member;
‫השתלת עדשות אינטראוקולריים בעלי‬
‫תמיכה טלסקופית‬
]33[
US
‫ יצחק ליפשיץ‬,‫ גדעון דותן‬,‫יוסף גרוס‬
,'‫ קולב ושות‬.‫סנפורד ט‬
‫ רחובות‬,2273 .‫ד‬.‫ ת‬, ‫ מרמורק‬,4 ‫שער הגיא‬
characterized by said telescope being
further attached to at least one second
carrying member (18), wherein said at
least one second carrying member is
adapted to be attached to a portion of the
eye.
__________
]11[]21[
1963
137276
November 20, 2005– ‫י"ח בחשון התשס"ו‬
]54[
EXTENSIBLE DISTRIBUTED
ENTERPRISE APPLICATION
INTEGRATION SYSTEM
]22[
]31[
18.11.1999
60/108993
]32[ 18.11.1998
412595
05.10.1999
412633
05.10.1999
Int. Cl.7 G06F 009/54, 015/163
SAGA SOFTWARE, INC., U.S.A.
WO/2000/029924
SANFORD T.COLB & CO.,,
P.O.B. 2273,
REHOVOT 76122
]51[
]71[
]87[
]74[
[57] A system for integrating a plurality
of computer applications, comprising: first
means for routing plurality of messages
within the system; means for storing a
plurality of data transformation
configurations and a plurality of business
process rules; means for applying said data
transformation configurations to said
plurality of messages; second means for
routing said plurality of messages between
said first means for routing messages
within the system and a plurality of
computer applications, wherein said
second means for routing said plurality of
‫מערכת שילוב יישומים מופצים של‬
‫מפעלים הניתנת להרחבה‬
]33[
US
US
US
,'‫ קולב ושות‬.‫סנפורד ט‬
‫ רחובות‬,2273 .‫ד‬.‫ ת‬, ‫ מרמורק‬,4 ‫שער הגיא‬
messages between said first means for
routing messages within the system and
the plurality of computer applications,
includes: an adapter configured for each of
the plurality of computer applications; an
agent service hosting said adapter; a
message definition for each of said
plurality of messages said adapter will
produce, receive, or reply to;
means for connecting said adapter to its
respective computer applications; and
means for implementing said adapter
through said connecting means.
__________
]11[]21[
November 20, 2005– ‫י"ח בחשון התשס"ו‬
137302
1964
]54[
APPARATUS FOR USE IN
CONNECTION WITH REMOVAL
OF ELEMENTS, ESPECIALLY
EXOGENOUS ANTIBODIES,
FROM BLOOD OR PLASMA
]22[
]31[
]51[
]71[
14.01.1999
0070/98
]32[ 20.01.1998
Int. Cl.7 A61M 001/34, B01D 024/16
MITRA MEDICAL TECHNOLOGY
AB, SWEDEN
WO/1999/036110
LUZZATTO & LUZZATTO,
P.O.B. 5352 BEER-SHEVA 84965
]87[
]74[
[57] An apparatus for removing elements
from blood or plasma or plasma flowing in
an extracorporeal blood circulation system
of a patient, said apparatus comprising a
container (1) comprising, in sequence, an
inlet chamber (31), an adsorption chamber
for receiving an adsorbent, and an outlet
chamber (32), said container also
comprising a plurality of filter units (11,
12) for filtering the blood or plasma,
including a first filter unit between the
outlet chamber and the adsorption chamber
and a second filter unit between the
adsorption chamber and the inlet chamber,
and a container wall portion that, with the
first filter unit, defines the outlet chamber,
said container wall portion comprising (a)
an inlet (15) and an outlet (16) adjacent
1965
‫ בייחוד נוגדנים‬,‫מתקן לסילוק גורמים‬
‫ מדם או פלסמה‬,‫אקסוגניים‬
]33[
DK
,‫לוצאטו את לוצאטו‬
‫ באר שבע‬,5352 .‫ד‬.‫ ת‬, ‫ עומר‬,‫גן תעשיה‬
one another, (b) a plurality of passages,
including a first passage that
communicates with a transfer channel that
extends from the first passage to the inlet
chamber, and a second passage that
communicates with the outlet chamber, (c)
a bypass channel having first and second
ends, and (d) valve means (21) for
connecting the inlet and the outlet with the
respective first and second passages in a
first arrangement of the valve means and
for connecting the inlet and the outlet with
the respective first and second ends of the
bypass channel in a second arrangement of
the valve means, said apparatus further
comprising means for controlling
movement of the valve means between
said first and second arrangements.
November 20, 2005– ‫י"ח בחשון התשס"ו‬
__________
]11[]21[
137332
‫בנזותיאדיאזולים ונגזרותיהם הכנתם‬
‫ותכשירי רוקחות המכילים אותם‬
]54[
BENZOTHIADIAZOLES AND
DERIVATIVES, THEIR
PREPARATION AND
PHARMACEUTICAL
COMPOSITIONS COMPRISING
THEM
]22[
]31[
]51[
01.02.1999
9802251.0
]32[ 03.02.1998
]33[ GB
Int. Cl.7 A61K 031/41, 031/433, A61P 043/00, C07D 403/10, 413/10, 417/00, 417/10,
473/10, 495/10
NOVARTIS AG, SWITZERLAND
WO/1999/040089
LUZZATTO & LUZZATTO,
,‫לוצאטו את לוצאטו‬
P.O.B. 5352 BEER-SHEVA 84965
‫ באר שבע‬,5352 .‫ד‬.‫ ת‬, ‫ עומר‬,‫גן תעשיה‬
]71[
]87[
]74[
[57] CRFI receptor antagonist
compounds of the formula
November 20, 2005– ‫י"ח בחשון התשס"ו‬
1966
wherein
X is O, S, N-CH3 CH=CH or Calk = Calk,
where the Alk independently are (C1-4)
alkyl, R1 and R1 and R2 independently, are
hydrogen, halogen, (C1-4) alkyl, (C1-4)
alkoxy or trifluoromethyl, and Het is a
radical having one of the formulae (a) to
(p) below:
wherein
R3 and R8, independently, are hydrogen or
(C1-4) alkyl,
R4 is hydrogen, (C1-4) alkyl, cyano, nitro,
formyl or (C1-4) alkylcarbonyl,
R5 and R6, independently, are hydrogen,
(C1-7) alkyl, (C3-7) alkenyl, (C3-7)
cycloalkyl, (C3-7) cycloalkyl (C1-4) alkyl,
(C1-4) alkoxy (C2-5) alkyl or benzyl,
R7 is hydrogen, hydroxy, (C1-4) alkyl or
(C1-4) alkoxy,
W is N, C-CN, C-NO2, C-COH or C-COAlk where Alk is as defined above, and
X is as defined above,
in free base or acid addition salt form.
__________
1967
November 20, 2005– ‫י"ח בחשון התשס"ו‬
]11[]21[
]54[
ABSORBENT ARTICLE WITH
BREATHABLE DUAL LAYER
BACKSHEET COMPRISING ONE
LAYER WITH SLANTED
CAPILLARY APERTURES
]22[
]31[
]51[
]71[
03.02.1999
98101867.4
]32[ 04.02.1998
Int. Cl.7 A61F 013/15
THE PROCTER & GAMBLE
COMPANY, U.S.A.
WO/1999/039673
REINHOLD COHN AND PARTNERS,
21 AHAD HA'AM ST.
P.O.BOX 4060,
TEL AVIV 61040
]87[
]74[
[57] Breathable disposable absorbent
article of layered construction, each layer
or system of layers having a garment
facing surface, which is oriented to face in
a direction of a garment (21) during use of
the article, and a wearer facing surface,
which is oriented to face in the direction of
the wearer during use of the article, said
article comprising at least an absorbent
core (40, 42, 44); a breathable backsheet
(50, 52) located on said garment facing
surface of said absorbent surface of said
core said backsheet comprising at least a
first backsheet layer (50) and a second
backsheet layer (52), said first backsheet
layer being positioned between said
garment facing surface of said absorbent
core and said wearer facing surface of said
second backsheet layer, said first and said
November 20, 2005– ‫י"ח בחשון התשס"ו‬
137399
‫פריט סופג בעל שיכבה אחורית כפולה‬
‫ונושמת והמכיל שיכבה אחת בעלת‬
‫פתחים קפילרים משופעים‬
]33[
EP
,‫ריינהולד כהן ושותפיו‬
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
second backsheet layers being water vapor
permeable, said first backsheet layer
comprising a resilient, three dimensional
web, said web consists of a liquid
impervious polymeric film having
apertures, said apertures forming
capillaries, said capillaries having walls
which extend away from said wearer
facing surface of said film, said capillaries
having a first opening in said garment
facing surface of said film and a second
opening at the end of said capillaries
spaced apart from said wearer facing
surface of said film said article being
characterized in that said capillaries extend
away from said wearer facing surface of
said film at an angle of less than 90o
measured from the plane of said film.
1968
__________
]11[]21[
]54[
TARGET DETECTION
ARRANGEMENT
]22[
]31[
]51[
]71[
02.02.1999
1008276
]32[ 11.02.1998
Int. Cl.7 G01S 017/02
THALES NEDERLAND B.V., THE
NETHERLANDS
WO/1999/041622
REINHOLD COHN AND
PARTNERS,
21 AHAD HA'AM ST.
P.O.BOX 4060,
TEL AVIV 61040
]87[
]74[
[57] Detection arrangement for the
remote detection of targets, comprising: a
radar signal generator, provided with a
COHO signal and STALO signal, for
generating coded RF radars signals; a
transmitter unit controlled by the coded RF
signals; a radar receiver unit; and a video
processor connected to the radar receiver
unit; and a video processor connected to
the radar receiver unit; the transmitter unit
being designed to transmit optical signals
modulated by the coded RF radar signals
1969
137408
‫מערך של גילוי מטרה‬
]33[
NL
,‫ריינהולד כהן ושותפיו‬
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
and an optical detector being positioned in
front of the radar receiver unit for
converting echo signals from the
transmitted optical signals into coded RF
radar signals, possibly containing target
information, characterized in that the RF
signals are, using the STALO signal,
mixed down to an intermediate frequency,
subsequently filtered and, along with the
COHO signal serving as reference signal,
applied to a quadrature detector to produce
quadrature video.
November 20, 2005– ‫י"ח בחשון התשס"ו‬
__________
]11[]21[
137422
-1-‫הידרוקסי‬-3-‫(ציס‬-) ‫תהליך להכנת‬
‫ פיפרידין‬- )‫טרימתוקסיפניל‬-2,4,6)-4-‫מתיל‬
]54[
METHOD FOR PRODUCING ()CIS-3-HYDROXY-1-METHYL-4(2,4,6-TRIMETHOXYPHENYL)PIPERIDINE
]22[
]31[
]51[
]71[
18.12.1998
19802449.5
]32[ 23.01.1998
]33[
Int. Cl.7 C07D 211/02, 211/42, 211/72, 211/74
AVENTIS PHARMA
DEUTSCHLAND GMBH, GERMANY
WO/1999/037615
EITAN, PEARL, LATZER AND
COHEN ZEDEK,
P.O.B. 12688
HERZLIYA 46733
]87[
]74[
DE
,‫ לצר וכהן צדק‬,‫ פרל‬,‫איתן‬
‫ הרצליה‬,12688 .‫ד‬.‫ ת‬, 7 ‫רחוב שנקר‬
[57] A process for the preparation of (-)
cis-3-hydroxy-1-methyl-4-(2, 4, 6trimethoxyphenyl) piperidine
November 20, 2005– ‫י"ח בחשון התשס"ו‬
1970
Which comprises
(a1) converting 1-methylpiperidin-4-one
into the hydrobromide according to known
processes, or
(a2) converting 1-methylpiperidin-4-one
(III) directly into the hydrobromide, prior
to the subequent bromination, by
introduction of 1-methylpiperidin-4-one
into an HBr glacial acetic acid solution,
and
(b) reacting 1-methylpiperidin-4-one
hydrobromide in a suitable solvent in the
temperature range from 0oC-30oC with
bromine to give 3(R, S)-bromo-1-methyl4-oxopiperidine hydrobromide
(c) reacting this intermediate directly by
addition of 0.8-1 equivalent of 1, 3,5trimethoxybenzene
to the reaction solution at 0o-30oC to give
3(R, S)-bromo-1-methyl-4- (2, 4, 6-
1971
trimethoxyphenyl)-1,2,3,6tetrahydropyridine hydrobromide
November 20, 2005– ‫י"ח בחשון התשס"ו‬
and, if appropriate, additionally adding
acetic anhydride to remove any water of
reaction formed
(d1) first isolating the compound (VI) as a
solid by stirring the reaction solution into a
suitable organic solvent, and subsequently
reacting the resulting product with water
and by stirring at 50o-100oC to give
3(R,S)-hydroxy-1-methyl-4-(2,4,6)trimethoxyphenyl)-1,2,3,6tetrahydropyridine
or
(d2) treating the reaction mixture
containing the compound (VI) directly
with water and reacting by stirring at 50o100oC to give 3(R, S)- hydroxy-1-methyl4-(2, 4,6-trimethoxyphenyl)-1,2,3,6tetrahydropyridine (VII), and
(d3) cooling the reaction mixtures obtained
according to (d1) or (d2), if appropriate
diluting further with water and adjusting to
pH>12 at 0o-30oC by addition of aqueous
alkali, 3(R, S)-hydroxy-1-methyl-4- (2, 4,
6-trimethoxyphenyl)-1,2,3,6tetrahydropyridine (VII) precipitating,
filtering off the resulting crude product
with suction and if appropriate, for
purification, taking it up again in aqueous
hydrochloric acid, filtering and optionally
extracting with a water-immiscible solvent,
and then adjusting the aqueous phase to
pH>12 by addition of aqueous alkali,
3(R,S)-hydroxy-1-methyl-4-(2, 4,6trimethoxyphenyl)-1,2,3,6tetrahydropyridine (VII) precipitating,
extracting the precipitated product, if
appropriate for further purification, by
stirring with one or more suitable organic
solvents or alternatively mixtures of these
solvents, and
(e1) catalytically hydrogenating the
resulting product (VII) in a suitable solvent
or mixtures of these solvents using a
suitable catalyst to give the racemic 3,4-cis
alcohol
November 20, 2005– ‫י"ח בחשון התשס"ו‬
1972
where the 3,4-trans alcohol, which
possibly results in srnall amounts during
the reduction, can be removed by
crystalliation from suitable solvents, or
(e2) for the hydrogenation, employing
easily accessible esters (IXa) or carbonates
(IXb) of the compound (VII)
in which R is (C1-C16) – alkyl, (C6-C14)aryl-(C1-C16)-alkyl or (C6-C14)-aryl and in
the formula (IXa) is further carboxy-(C2C6)- alkyl,
compounds (Xa) and (Xb) being obtained,
from which the compound (VII) can be
liberated by known procedures,
(f1) obtaining the enantiomerically pure cis
alcohol (II) from the compound (VIII) by a
known process by resolution using suitable
chiral auxiliary reagents; or
(f2) carrying out the resolution using the
compounds
1973
November 20, 2005– ‫י"ח בחשון התשס"ו‬
where R is (C1-C16)-alkyl, (C6-C14)-aryl(C1-C16)-alkyl or (C6-C14)-aryl and in the
formula (Xa) is further carboxy-(C2-C6)alkyl,
and then converting these into the
compound (II) by known processes,
it also being possible to exchange the
sequence of the reaction steps e) and f), i.e.
also to carry out the resolution as early as
at the stage of the allyl alcohol (VII) or of
the compounds (IXa) and (IXb) obtained
therefrom. Claimed as novel are the
compounds
3(R,S)-bromo-1-methyl-4-(2, 4, 6trimethoxyphenyl)-1,2,3,6tetrahydropyridine hydrobromide (VI) and
3(R,S)-hydroxy-1-methyl-4-(2, 4, 6trimethoxyphenyl)-1,2,3,6tetrahydropyridine (VII).
__________
]11[]21[
137453
‫השימוש בתכשירים אבקתיים המכילים‬
‫הידרוקסיפירידונים להכנת תרופה לטפול‬
‫בכיבי רגליים ופצעי לחץ‬
]54[
UTILIZATION OF POWDER
PREPARATIONS CONTAINING
HYDROXYPYRIDONES FOR THE
PRODUCTION OF A
MEDICAMENT FOR THE
TREATMENT OF LEG ULCERS
AND DECUBITUS ULCERS
]22[
]31[
]51[
]71[
11.01.1999
19802708.7
]32[ 24.01.1998
]33[ DE
Int. Cl.7 A61K 009/18, 031/44, A61P 031/00, C07D 213/00, 213/89
AVENTIS PHARMA
DEUTSCHLAND GMBH, GERMANY
WO/1999/037300
EITAN, PEARL, LATZER AND
,‫ לצר וכהן צדק‬,‫ פרל‬,‫איתן‬
COHEN ZEDEK,
‫ הרצליה‬,12688 .‫ד‬.‫ ת‬, 7 ‫רחוב שנקר‬
P.O.B. 12688
HERZLIYA 46733
]87[
]74[
[57] The use of powder and at least one
1-hydroxy-2-pyridone of the formula
or a salt thereof, where R1, R2 and R3,
which are identical or different, are a
November 20, 2005– ‫י"ח בחשון התשס"ו‬
hydrogen atom or alkyl with 1-4 carbon
atoms, and
1974
R4 is a saturated hydrocarbon radical with
6 to 9 carbon atoms or a radical of the
formula
where
X is S or O,
Y is a hydrogen atom or up to 2 halogen
atoms,
Z is a single bond or the divalent radical
being O,S,-CR2-, in which R is hydrogen
or (C1-C4)-alkyl, or other divalent radical
with 2-10 C and, optionally, O and/or S
atoms linked in the form of a chain,
wherein – if the radicals contain 2 or more
O and/or S atoms – the latter are separated
from one another by at least 2 C atoms,
and it also being possible for 2 adjacent C
atoms to be linked together by a double
bond, and the free valencies of the C atoms
being saturated by a hydrogen atom and/or
(C1-C4)- alkyl groups,
Ar is an aromatic ring system which has up
to two rings and which may be substituted
by up to three radicals from the group of
fluorine, chlorine, bromine, methoxy, (C1C4)-alkyl, trifluoromethyl and
trifluoromethoxy, for the production of a
medicament for the treatment of leg ulcers
and/or decubitus ulcers, wherein the ulcer
is not infected.
__________
]11[]21[
]54[
METHOD AND APPARATUS FOR
INTEGRATING MANUAL INPUT
]22[
]31[
25.01.1999
60/072509
]32[ 26.01.1998
236513
25.01.1999
Int. Cl.7 G09G 005/00
WAYNE WESTERMAN, U.S.A.
JOHN G. ELIAS, U.S.A.
]51[
]71[
]87[
]74[
WO/1999/038149
REINHOLD COHN AND PARTNERS,
21 AHAD HA'AM ST.
P.O.BOX 4060,
TEL AVIV 61040
[57] A sensing device that is sensitive to
changes in self-capacitance brought about
by changes in proximity of a touch device
to the sensing device, the sensing device
comprising: two electrical switching
means (30, 31) connected together in series
1975
137478
‫שיטה והתקן לשילוב קלט ידני‬
]33[
US
US
,‫ריינהולד כהן ושותפיו‬
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
having a common node (48), an input node
(46), and an output node (45); a dielectriccovered sensing electrode (33) connected
to the common node between the two
switching means; a power supply (34)
providing an approximately constant
November 20, 2005– ‫י"ח בחשון התשס"ו‬
voltage connected to the input node of the
series-connected switching means; an
integrating capacitor (37) to accumulate
charge transferred during multiple
consecutive switching of the series
connected switching means; another
switching means (36) connected in parallel
across the integrating capacitor to deplete
its residual charge; and a voltage-tovoltage translation device (35) connected
to the output node of the series-connected
switching means which produces a voltage
representative of the proximity of the
touch device (38) to the sensing device.
__________
]11[]21[
]54[
READOUT SYSTEM FOR SOLID
STATE DETECTOR ARRAYS
]22[
]51[
]71[
30.07.2000
Int. Cl.7 G01T 001/00
INTEGRATED DETECTOR &
ELECTRONICS (IDE) S.A.,
NORWAY
ORBOTECH MEDICAL
SOLUTIONS LTD.
SANFORD T.COLB & CO.,,
P.O.B. 2273,
REHOVOT 76122
]74[
[57] A signal readout system for a solid
state detector array, comprising: a plurality
of detection channels (50); and a switching
network comprising an arbitrator (54) and
a plurality of multiplexer units (56),
wherein said arbitrator directs the
November 20, 2005– ‫י"ח בחשון התשס"ו‬
137580
‫מערכת קריאה למערך גלאי מצב מוצק‬
‫אורבוטק מדיקל סלושנס בע"מ‬
,'‫ קולב ושות‬.‫סנפורד ט‬
‫ רחובות‬,2273 .‫ד‬.‫ ת‬, ‫ מרמורק‬,4 ‫שער הגיא‬
outputs of at least two of said plurality of
detection channels into at least two of said
plurality of multiplexer units according to
the content of said at least two detection
channels, such that data are output
simultaneously from at least two of said
plurality of detection channels.
1976
__________
]11[]21[
]54[
INTEGRAL CONTAINER FOR
TOILET RIM BLOCK
]22[
]51[
]71[
14.08.2000
Int. Cl.7 E03D 009/03
SANO BRUNO'S ENTERPRISES
LTD.
REINHOLD COHN AND
PARTNERS,
21 AHAD HA'AM ST.
P.O.BOX 4060,
TEL AVIV 61040
]74[
[57] An integral mold cast container (10)
for a block of chemical adapted for gradual
washing out of said chemical by flushing a
liquid through the container, said container
comprising a first (12) and a second (14)
cup-shaped section, each section having a
1977
137841
‫מיכל חומר חיטוי אינטגרלי לאסלה‬
‫ תל אביב‬,‫סנו מפעלי ברונוס בע"מ‬
,‫ריינהולד כהן ושותפיו‬
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
bottom part (18), side walls (20, 22) with
rims (24, 26), and an open part, wherein
said sections are connected by a hinge (40)
that connects the bottom of the first section
to a rim of the second section.
November 20, 2005– ‫י"ח בחשון התשס"ו‬
__________
]11[]21[
]54[
PROCESS FOR PREPARING 4, 6 DICHLORO- 5 FLUOROPYRIMIDINE
]22[
]31[
15.08.2000
19939190.4
]32[ 18.08.1999
19948933.5
11.10.1999
Int. Cl.7 C07D 239/30
BAYER AKTIENGESELLSCHAFT,
GERMANY
REINHOLD COHN AND PARTNERS,
21 AHAD HA'AM ST.
P.O.BOX 4060,
TEL AVIV 61040
]51[
]71[
]74[
November 20, 2005– ‫י"ח בחשון התשס"ו‬
137866
- 5 - ‫ דיכלורו‬- 4 ,6 - ‫תהליך להכנת‬
‫פלואורופירמידין‬
]33[
DE
DE
,‫ריינהולד כהן ושותפיו‬
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
1978
[57] Process for preparing 4,6-dichloro5-fluoro-pyrimidine of the formula
characterized in that
(a) compounds of the formula
in which R represents methyl or ethyl are
reacted with formamide in the presence of
alkali metal alkoxides in a diluent at
elevated temperature, if appropriate under
pressure, and the reaction mixture is
acidified with an acid after the reaction,
where from 2.5 to 8 mol of formamide are
employed per mole of the compound of the
formula (II) and the compound of the
formula (II) is added by metered addition
over a period of from 2 to 4 hours, and
(b) the resulting 4,6-dihydroxy-5fluoropyrimidine
is reacted with phosphorus oxychloride,
and the resulting reaction mixture is
subsequently reacted with chlorine in the
presence of phosphorus trichloride such
that in each case at most 99.9% by weight
of the chlorophosphonic acid which is
present in the reaction mixture are
converted, and the resulting reaction
mixture is worked up distillatively,
whereby the 4,6-dichloro-5fluoropyrimidine formed is separated off
and the phosphorus oxychloride is
recovered.
__________
1979
November 20, 2005– ‫י"ח בחשון התשס"ו‬
]11[]21[
]54[
DIGITAL ELECTRONIC
CONTROL UNIT
]22[ 05.07.1999
]51[ Int. Cl.7 F24F 011/02, G05D 029/00
]71[ VASU TECH LIMITED, INDIA
]87[ WO/2001/002924
]74[ WOLFF, BREGMAN AND
GOLLER,
KEREN HAYESOD ST 19B,
P.O.B. 1352
JERUSALEM 91013
[57] A digital electronic control unit for
an appliance, comprising: a plurality of
sensor drive circuits (2a-2d) each driving
one of a plurality of sensing elements (1a1d) external to said digital electronic
control unit, each sensing element
converting a sensed parameter to an
electrical signal; an analog multiplexer (3)
that receives the electrical signal from each
external sensing element and selectively
routes a selected electrical signal to a
multiplexer output; an analog-to-digital
converter (4) connected to the output of
said analog multiplexer and converting the
selected electrical signal to digital values;
a linearity, sensitivity and offset correction
circuit (5) connected to the output of said
analog-to-digital converter for correcting
the digital values received from it, using
sensor calibration data stored in a nonvolatile memory (17); a central-control
unit (6) that receives corrected output from
November 20, 2005– ‫י"ח בחשון התשס"ו‬
137899
‫יחידת בקרה אלקטרונית ספרתית‬
,‫ ברגמן וגולר‬,‫וולף‬
‫ ירושלים‬,1352 .‫ד‬.‫ ת‬, '‫ב‬19 ‫רחוב קרן היסוד‬
said linearity, sensitivity and offset
correction circuit, and generates control
signals for operating the appliance, as well
as selection signals for controlling said
analog multiplexer, using control data
supplied by the non-volatile memory; a
digital de-multiplexer (8) connected to an
output of said central control unit for
selecting one of a plurality of demultiplexer outputs to which a demultiplexer input coupled to said central
control unit is to be connected; a plurality
of control latches (9a-9f) each connected at
one of said de-multiplexer outputs, for
storing the digital data received from it and
actuating a part of the appliance to adjust
the sensed parameter; a non-volatile
memory (17) that stores data and control
parameters for the operation of said central
control unit, linearity, sensitivity and offset
correction circuit.
1980
__________
]11[]21[
]54[
SYSTEM AND METHOD FOR
HEAT CONTROL OF A LIVING
BODY
]22[
]31[
29.01.1999
123573
]32[ 05.03.1998
126783
27.10.1998
Int. Cl.7 A61F 007/00
M.T.R.E. ADVANCED
TECHNOLOGIES LTD.
]51[
]71[
]87[
]74[
WO/1999/044552
REINHOLD COHN AND
PARTNERS,
21 AHAD HA'AM ST.
P.O.BOX 4060,
TEL AVIV 61040
[57] A system for controlling an
individual's body core temperature (BCT)
comprising: a heat exchanger (20) for
transferring heat to or removing heat from
portions of the individual's body surface; at
least one BCT-sensing device for
measuring the individual's actual BCT
(aBCT) and emitting an aBCT data signal;
at least one sensing device for measuring a
parameter indicative of the heat transfer
1981
137948
‫מערכת ושיטה לבקרת חום של גוף חי‬
]33[
IL
IL
,‫ טכנוגלוגיות מתקדמות בע"מ‬.‫אי‬.‫אר‬.‫טי‬.‫אמ‬
‫קיסריה‬
,‫ריינהולד כהן ושותפיו‬
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
dynamics (HTD) between the body surface
and the body's core, and emitting an HTD
data signal; and a control module (48) for
receiving data signal from measuring
devices, comprising the aBCT data signal
and the HTD data signal, and for emitting
a control signal for controlling heat
exchange properties of said heat exchanger
as a function of the data signals and a
desired body core temperature (dBCT).
November 20, 2005– ‫י"ח בחשון התשס"ו‬
__________
]11[]21[
]54[
METHOD FOR PRODUCING
SPHERICAL PELLETS WITH A
POLYMERIC COATING
]22[
]31[
]51[
]71[
24.02.1999
19808634.2
]32[ 24.02.1998
Int. Cl.7 A61K 009/00
SCHERING
AKTIENGESELLSCHAFT,
GERMANY
WO/1999/043303
WOLFF, BREGMAN AND GOLLER,
KEREN HAYESOD ST 19B,
P.O.B. 1352
JERUSALEM 91013
]87[
]74[
[57] A process for the production of
encased, spherical granular grains
comprising:
(a) spraying crude grains, which consist of
at least one prostane derivative as
pharmaceutical active ingredient and
cyclodextrin as a vehicle, which form
together a prostane-cyclodextrin-clathrate,
and optionally pharmaceutically
compatible additives and/or vehicles, with
an aqueous polymer dispersion and
additives which comprise an ethyl
cellulose and/or a poly(meth) acrylic acid
137965
‫תהליך להכנת גלולות עגולות עם צפוי‬
‫פולומרי‬
]33[
DE
,‫ ברגמן וגולר‬,‫וולף‬
‫ ירושלים‬,1352 .‫ד‬.‫ ת‬, '‫ב‬19 ‫רחוב קרן היסוד‬
ester as a polymer, in a fluidized bed or
boiling bed,
(b) applying said polymer dispersion to
obtain a polymer thickness in the range of
1 to 5% (w/w) of the total mass and
wherein the total mass corresponds to the
composition of the encased grains, and
(c) curing the grains that are encased with
said polymer dispersion at a temperature of
45 to 65˚C for at least 24 hours and
wherein said grains have a pharmaceutical
active ingredient release profile which
remains unchanged over the storage time.
__________
November 20, 2005– ‫י"ח בחשון התשס"ו‬
1982
]11[]21[
137988
‫פוליאוריתנים הקשורים בקשר קוולנטי‬
‫לחומצה היאלורונית המכילה סולפט או‬
‫ תהליך‬,‫לנגזרות שלה המכילות סולפט‬
‫להכנתם וחומרים המוקומפטיביליים‬
‫המכילים אותם‬
]54[
POLYURETHANES BOUND
COVALENTLY TO SULPHATED
HYALURONIC ACID OR
SULPHATED HYALURONIC ACID
DERIVATIVES, PROCESS FOR
THEIR PREPARATION AND
HAEMOCOMPATIBLE
MATERIALS COMPRISING THE
SAME
]22[
]31[
]51[
]71[
24.02.1999
PD98A000037 ]32[ 25.02.1998
]33[ IT
Int. Cl.7 A61L 027/00, 033/00, 033/06, C08G 002/30, 018/28, 018/83
FIDIA ADVANCED BIOPOLYMERS
S.R.L., ITALY
WO/1999/043728
LUZZATTO & LUZZATTO,
,‫לוצאטו את לוצאטו‬
P.O.B. 5352 BEER-SHEVA 84965
‫ באר שבע‬,5352 .‫ד‬.‫ ת‬, ‫ עומר‬,‫גן תעשיה‬
]87[
]74[
[57] A polyurethane bound covalently to
sulphated hyaluronic acid or to a sulphated
hyaluronic acid derivative.
__________
]11[]21[
]54[
]22[
]31[
]51[
]71[
]87[
]74[
[57]
METHOD AND APPARATUS FOR
DOWNCONVERTING SIGNALS
TRANSMITTED USING A
PLURALITY OF MODULATION
FORMATS TO A COMMON
INTERMEDIATE FREQUENCY
RANGE
02.03.1999
60/076520
]32[ 02.03.1998
259242
26.02.1999
Int. Cl.7 H04B 001/40, H04L 027/00
QUALCOMM INCORPORATED,
U.S.A.
WO/1999/045654
SANFORD T.COLB & CO.,,
P.O.B. 2273,
REHOVOT 76122
A receiver that downconverts signals
1983
138019
‫שיטה והתקן להמרת אותות המשודרים‬
‫באמצעות מגוון תצורות אפנון לטווח תדר‬
‫תווך משותף‬
]33[
US
US
,'‫ קולב ושות‬.‫סנפורד ט‬
‫ רחובות‬,2273 .‫ד‬.‫ ת‬, ‫ מרמורק‬,4 ‫שער הגיא‬
modulated using a plurality of modulation
November 20, 2005– ‫י"ח בחשון התשס"ו‬
formats to a common intermediate
frequency range, comprising: a first band
selection filter that selects a first frequency
range; a second band selection filter that
selects a second frequency range; a third
band selection filter that selects a third
frequency range; a first downconverter,
coupled to an output of the first band
selection filter, that downconverts signals
from the first frequency range to the
common intermediate frequency range; a
second downconverter, selectively coupled
to a switch to either an output of the
second band selection filter or an output of
the third band selection filter, that
downconverts signals from either the
second frequency range or the third
frequency range to the common
intermediate frequency range,wherein the
second downconverter has an input
coupled to a frequency doubling circuit;
switching circuitry that selectively couples
one of either a first oscillating signal from
a voltage controller oscillator (VCO)
having VCO frequency range or a second
oscillating signal at a second frequency
that is outside the VCO frequency range to
an input of the first downconverter and an
input of the frequency doubling circuit.
__________
]11[]21[
138068
‫תרכובות אמינו ציקליות ותכשריי רוקחות‬
‫המכילים אותן‬
]54[
CYCLIC AMINO COMPOUNDS
AND PHARMACEUTICAL
COMPOSITIONS CONTAINING
THE SAME
]22[
]31[
]51[
26.02.1999
10-46921
]32[ 27.02.1998
]33[ JP
Int. Cl.7 A61K 031/395, A61P 009/10, 043/00, C07D 205/04, 207/12 , 211/54, 211/72,
471/08
UBE INDUSTRIES LTD., JAPAN
SANKYO COMPANY LIMITED,
JAPAN
WO/1999/043648
WOLFF, BREGMAN AND GOLLER,
,‫ ברגמן וגולר‬,‫וולף‬
KEREN HAYESOD ST 19B,
‫ ירושלים‬,1352 .‫ד‬.‫ ת‬, '‫ב‬19 ‫רחוב קרן היסוד‬
P.O.B. 1352
JERUSALEM 91013
]71[
]87[
]74[
November 20, 2005– ‫י"ח בחשון התשס"ו‬
1984
[57] Platelet aggregation inhibiting cyclic
amino compounds of the formula
wherein: R1 represents a phenyl group
which may optionally be substituted by at
least one substituent selected from the
group consisting of halogen atoms, C1-C4
alkyl groups, fluoro-substituted –( C1-C4
alkoxy) groups, cyano groups and nitro
groups;
R2 represents a C1-C8 aliphatic acyl group
which may optionally be substituted by at
least one substituent selected from the
group consisting of halogen atoms, C1-C4
alkoxy groups and cyano groups, a benzoyl
group which may optionally be substituted
by at least one substituent selected from
the group consisting of halogen atoms, C1C4 alkyl groups and C1-C4 alkoxy groups,
or a (C1-C4 alkoxy) carbonyl group; and
R3 represents a saturated cyclic amino
group having in total from 2 to 8 carbon
atoms in one or more rings, the largest
nitrogen-containing ring having from 3 to
7 ring atoms, said saturated cyclic amino
group being substituted by a group having
the formula –S-X-R4 wherein R4 and X are
as defined below, said saturated cyclic
amino group being attached via a ring
nitrogen atom thereof to the adjacent
carbon atom to which substituents R1 and
R2 are attached, and said saturated cyclic
amino group optionally containing a
further ring heteroatom selected from the
group consisting of oxygen, nitrogen and
sulfur atoms,
R4 represents a phenyl group which may
optionally be substituted by at least one
substituent selected from the group
consisting of halogen atoms, C1-C4 alkyl
groups, C1-C4 alkoxy groups, nitro groups
and cyano groups, a C1-C6 alkyl group
which may optionally be substituted by at
least one substituent selected from the
group consisting of amino groups,
hydroxyl groups, carboxyl groups, (C1-C4
alkoxy) carbonyl groups, substituents
having the formula –NH-A1 (wherein, A1
represents an α-amino acid residue), or
a C3-C8 cycloalkyl group, and X represents
a sulfur atom, a sulfinyl group or a
sulfonyl group, and said cyclic amino
group may optionally be further substituted
by a group having the formula =CR5R6,
wherein R5 and R6 are the same or
different and each independently
represents a hydrogen atom, a C1-C4 alkyl
group, a carboxyl group, a (C1-C4 alkoxy)
carbonyl group, a carbamoyl group, a (C1C4 alkyl) carbamoyl group or a di-( C1-C4
alkyl)carbamoyl group; or a
pharmacologically acceptable salt thereof.
__________
1985
November 20, 2005– ‫י"ח בחשון התשס"ו‬
]11[]21[
]54[
APPARATUS AND METHOD FOR
IMPROVED CONNECTIVITY IN
WIRELESS OPTICAL
COMMUNICATION SYSTEMS
]22[
]31[
]51[
]71[
21.04.1999
99100423.5
]32[ 11.01.1999
Int. Cl.7 H04B 010/10
INTERNATIONAL BUSINESS
MACHINES CORPORATION, U.S.A.
WO/2000/042719
SANFORD T.COLB & CO.,,
P.O.B. 2273,
REHOVOT 76122
]87[
]74[
[57] Apparatus for receiving an infrared
signal (S1, S2, S3) comprising at least two
receiving units (1,2,3), each comprising a
converter (12, 22, 32)-which converts the
received infrared signal (S1, S2, S3) to a
digital signal (RxS_1, RxS_2, RxS_3),
whereby the digital signals represent data
carried in frames comprising at least a data
field and a heater field which contains a
November 20, 2005– ‫י"ח בחשון התשס"ו‬
138080
‫התקן ושיטה לחיבור משופר במערכת‬
‫תקשורת אופטיות אלחוטיות‬
]33[
EP
,'‫ קולב ושות‬.‫סנפורד ט‬
‫ רחובות‬,2273 .‫ד‬.‫ ת‬, ‫ מרמורק‬,4 ‫שער הגיא‬
preamble being identical for each of said
digital signals, and a selector (Fig 2) for
determining for at least part of each of the
preambles a measure (A, B, C) related to
its signal-to-noise ratio and comparing the
measures (A, B, C) in order to select for
further processing the one digital signal
(RxS_1) with the highest signal-to-noise
ratio.
1986
__________
]11[]21[
138137
‫אמידים של חומצה כולנית ותכשיר‬
‫רוקחות שלהם‬
]54[
CHOLENIC ACID AMIDES AND
PHARMACEUTICAL
COMPOSITIONS THEREOF
]22[
]31[
]51[
]71[
08.03.1999
9804861.4
]32[ 06.03.1998
]33[ GB
Int. Cl.7 A61K 031/57, 031/58, C07J 041/00, 043/00
RESEARCH INSTITUTE FOR
MEDICINE AND CHEMISTRY INC.,
U.S.A.
WO/1999/045024
EITAN, PEARL, LATZER AND
,‫ לצר וכהן צדק‬,‫ פרל‬,‫איתן‬
COHEN ZEDEK,
‫ הרצליה‬,12688 .‫ד‬.‫ ת‬, 7 ‫רחוב שנקר‬
P.O.B. 12688
HERZLIYA 46733
]87[
]74[
[57] Compounds of the formula
1987
November 20, 2005– ‫י"ח בחשון התשס"ו‬
in which: R1 represents a hydroxyl group
or protected hydroxyl group, R2 represents
a hydrogen atom and a double bond is
present at c, or R1 and R2 together
represent an oxo group and a double bond
is present at b or double bonds are present
at a and b;
R3 represents a methyl group having α- or
β-configuration;
R4 and R5, which may be the same or
different, are selected from hydrogen
atoms and aliphatic, cycloaliphatic,
araliphatic and aryl groups, or together
with the nitrogen atom to which they are
attached form a heterocyclic group; and
X represents a polymethylene group
containing 2-5 carbon atoms, an oxa
group-containing analogue thereof in
which a methylene group other than that
attached to the –CO.NR4R5 moiety is
replaced by an oxygen atom, or an
unsaturated analogue thereof containing up
to two double bonds, with the provisos
that:
(i) when R3 is α-CH3 and X is (CH2)2 then
R4R5N- does not represent an amino,
dimethylamino, diethylamino, imidazolyl
or triazolyl group;
(ii) when R3 is α-CH3 and X is (CH2)3 then
R4R5N- is not morpholino; and
(iii) when R3 is α-CH3 and X is O (CH2)2
then R4R5N is not dimethylamino.
__________
]11[]21[
]54[
STAPLES FOR BONE FIXATION
]22[
]51[
]71[
07.09.2000
Int. Cl.7 A61B 017/15, 017/84
NITI ALLOYS TECHNOLOGIES
LTD.
LEONID MONASSEVITCH, ZVI
LASTER, MICHAEL ARAD
JEREMY M. BEN-DAVID & CO.
LTD.,
HAR HOTZVIM HI-TECH PARK,
P.O. B0X 45087 JERUSALEM
]72[
]74[
[57] Apparatus for increasing a length
span of a staple (10), which includes:
proximal and distal ends with respect to a
user, which define a z-axis of an x; y; z
coordinate system between them; and first
and second prongs (14, 16), joined by a
system which provides a mechanical
advantage to selectably bringing said first
and second prongs together and pushing
them apart, wherein said first prong further
includes, at said distal end, a staple
receptor, with a channel, for mounting
November 20, 2005– ‫י"ח בחשון התשס"ו‬
138320
‫מהדקים לחיבור עצם‬
‫ נתניה‬,‫טכנולוגיות סגסוגות ניטי בע"מ‬
‫ מיכאל ערד‬,‫ צבי לסטר‬,‫לאוניד מונסביץ‬
,‫דוד ושות' בע"מ‬-‫ בן‬.‫ירמיהו מ‬
‫ ירושלים‬,45087 .‫ד‬.‫ ת‬, ‫הר חוצבים‬
said staple thereon, said channel defining
an x-axis of the x; y; z coordinate system,
parallel to said staple length span, and
perpendicular to the direction of bringing
first and second prongs together and
pushing them apart, wherein said second
prong further includes, at said distal end, a
thin, cam-like head, having a width span
that increases in the direction of increasing
y, operable to increase said staple length
span, and wherein, as said first and second
prongs are brought together, said thin,
1988
cam-like head is arranged to slide between
said staple receptor and said staple,
mounted thereon, so as to wedge between
said staple receptor and said staple and
increase the length span of said staple.
__________
]11[]21[
]54[
SOFTWARE DRIVEN
PROTOCOL FOR MANAGING A
VIRTUAL CLINICAL NEUROPSYCHOLOGICAL TESTING
PROGRAM AND
APPURTENANCES FOR USE
THEREWITH
]22[
]51[
]71[
07.09.2000
Int. Cl.7 A61B 005/00
NEUROTRAX CORPORATION,
U.S.A.
ELY SIMON
JEREMY M. BEN-DAVID & CO.
LTD.,
HAR HOTZVIM HI-TECH PARK,
P.O. B0X 45087 JERUSALEM
]72[
]74[
[57] A software driven protocol for
managing a virtual clinical neuropsychological testing program, the
protocol including for each client of a
plurality of clients the steps:
(a) evaluating of a prior history of the
client;
(b) according to the evaluated prior
1989
138322
‫פרוטוקול תוכנה וירטואלית לניהול תכנית‬
‫מבחן קלינית בנוירו פסיכולוגי וכלים‬
‫לשימוש בה‬
,‫דוד ושות' בע"מ‬-‫ בן‬.‫ירמיהו מ‬
‫ ירושלים‬,45087 .‫ד‬.‫ ת‬, ‫הר חוצבים‬
history, forming an appropriate battery of
tests for testing the client wherein said
battery incorporates pseudo-randomization
of at least one representational or
organizational parameter;
(c) via a data-communications medium,
interactively
(i) delivering, to the client, the formed
November 20, 2005– ‫י"ח בחשון התשס"ו‬
battery of tests, and
(ii) accepting, from the client, a
substantially completed response to the
delivered formed battery of tests;
(d) analyzing the accepted response; and
(e) into the prior history of the client,
integrating
(i) the accepted substantially completed
response or
(ii) at least one analytical metric thereof.
__________
]11[]21[
138411
‫מערכת ושיטת מוליך ראשי בעלות מהירות‬
‫לשימוש במתח ויחסי עיתוי מתנודדים עבור‬
‫גילוי אותות‬
]54[
HIGH SPEED BUS SYSTEM AND
METHOD FOR USING VOLTAGE
AND TIMING OSCILLATING
REFERENCES FOR SIGNAL
DETECTION
]22[
]31[
08.03.1999
057158
]32[ 07.04.1998
]33[ US
60/078213
16.03.1998
US
165705
02.10.1998
US
Int. Cl.7 H03M 009/00, H04L 025/02, 025/06
JAZIO, INC., U.S.A.
WO/1999/048260
REINHOLD COHN AND PARTNERS,
,‫ריינהולד כהן ושותפיו‬
21 AHAD HA'AM ST.
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
P.O.BOX 4060,
TEL AVIV 61040
]51[
]71[
]87[
]74[
[57] A method, comprising: using a
master device to transmit a control signal
via a control bus to a first slave device;
transmitting a first oscillating reference for
detecting transitions in the control signal
via a first reference bus to the first slave
device; using the master device to transmit
a first data signal associated with the
control signal via a first data bus to the
first slave device; and transmitting a
second oscillating reference for detecting
transitions in the first data signal via a
second reference bus to the first slave
device.
_________
November 20, 2005– ‫י"ח בחשון התשס"ו‬
1990
]11[]21[
‫תווית מרובדת אלסטית‬
]54[
ELASTIC TAB LAMINATE
]22[
]31[
]51[
]71[
01.09.1998
09/049727
]32[ 27.03.1998
Int. Cl.7 A61F 002/00, 013/56, 013/66
MINNESOTA MINING AND
MANUFACTURING COMPANY,
U.S.A.
WO/1999/048455
REINHOLD COHN AND PARTNERS,
21 AHAD HA'AM ST.
P.O.BOX 4060,
TEL AVIV 61040
]87[
]74[
138450
[57] An extensible elastic tab (10)
comprising a coextruded extensible elastic
film comprising at least one elastic layer
(11) and at least one second layer (15) on
at least a first face of the elastic layer, the
coextruded elastic film is attached to at
least a partially extensible nonwoven layer
on at least one face the partially extensible
nonwoven layer (7) having a first direction
and a second direction the partially
extensible nonwoven layer having at least
one first portion being extensible in the
first direction to an extension limit and at
least one second inextensible portion (18)
in the first direction, wherein the
coextruded elastic and the nonwoven layer
when stretched to the extension limit of the
]33[
US
,‫ריינהולד כהן ושותפיו‬
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
nonwoven layer first portion(s) in the first
direction will elastically recover at least
1.0 cm, providing an elastic table having a
Useful Stretch Ratio (USR) of at least 30
percent, wherein the USR is defined as the
ratio of the useful range of elasticity to the
initial extension length of the first portion
at the upper extension limit, wherein the
useful range of elasticity includes the
portion of the elastic recovery length
having an elastic recovery force of greater
than 20 grams/cm force up to the upper
extension limit where the upper extension
limit is where the extensible elastic tab has
an incremental extension force of about
300 grams/cm to 350 grams/cm.
__________
1991
November 20, 2005– ‫י"ח בחשון התשס"ו‬
]11[]21[
]54[
SUSTAINED RELEASE
FORMULATIONS CONTAINING
MACROLIDE COMPOUNDS
]22[
]31[
25.03.1999
10-79039
]32[ 26.03.1998
10-182963
29.06.1998
Int. Cl.7 A61K 031/40
FUJISAWA PHARMACEUTICAL
CO., LTD., JAPAN
WO/1999/049863
WOLFF, BREGMAN AND GOLLER,
KEREN HAYESOD ST 19B,
P.O.B. 1352
JERUSALEM 91013
]51[
]71[
]87[
]74[
138466
‫תכשירים לשחרור ממושך המכילים‬
‫תרכובות מקרולידיות‬
]33[
JP
JP
,‫ ברגמן וגולר‬,‫וולף‬
‫ ירושלים‬,1352 .‫ד‬.‫ ת‬, '‫ב‬19 ‫רחוב קרן היסוד‬
[57] A sustained-release formulation of a
macrolide compound, wherein the time
(T63.2%) required for 63.2% of the
maximum amount of macrolide compound
to be dissolved is 0.7 to 15 hours, as
measured according to the Japanese
Pharmacopoeia, the 13-th edition,
Dissolution Test, No. 2 (Paddle method 50
rpm) using a test solution which is an
aqueous 0.005% hydroxypropyl cellulose
solution adjusted to pH 4.5, in which the
macrolide compound is a tricyclic
compound of the general formula
or a pharmaceutically acceptable salt
thereof, wherein each of adjacent pairs of
R1 and R2, R3 and R4, and R5 and R6
independently
(a) is two adjacent hydrogen atoms, but R2
may also be an alkyl group or
(b) may form another bond formed
between the carbon atoms to which they
are attached;
R7 is a hydrogen atom, a hydroxyl group, a
protected hydroxyl group, or an alkoxy
group, or an oxo group together with R1;
R8 and R9 are independently a hydrogen
atom or a hydroxyl group;
R10 is a hydrogen atom, an alkyl group, an
alkyl group substituted by one or more
hydroxyl groups, an alkenyl group, an
alkenyl group substituted by one or more
November 20, 2005– ‫י"ח בחשון התשס"ו‬
1992
hydroxyl groups, or an alkyl group
substituted by an oxo group;
X is an oxo group, (a hydrogen atom and a
hydroxyl group), (a hydrogen atom and a
hydrogen atom), or a group represented by
the formula –CH2-O-;
Y is an oxo group (a hydrogen atom and a
hydroxyl group), (a hydrogen atom and a
hydrogen atom), or a group represented by
the formula N-NR11R12 or N-OR13;
R11 and R12 are independently a hydrogen
atom, an alkyl group, an aryl group or a
tosyl group;
R13, R14, R15, R16, R17, R18, R19, R22 and R23
are independently a hydrogen atom or an
alkyl group;
R24 is an optionally substituted ring system
which may contain one or more
heteroatoms;
n is an integer of 1 or 2; and in addition to
the above definitions, Y, R10 and R23,
together with the carbon atom to which
they are attached, may represent a
saturated or unsaturated 5- or 6-membered
nitrogen, sulfur- and/or oxygen-containing
heterocyclic ring optionally substituted by
one or more groups selected from the
group consisting of an alkyl, a hydroxyl,
an alkoxy, a benzyl, a group of the formula
–CH2Se (C6H5), and an alkyl substituted
by one or more hydroxyl groups, which
comprises a solid dispersion composition,
wherein the macrolide compound (I) is
present as an amorphous state in a waterinsoluble base, in which the waterinsoluble base comprised in the solid
dispersion composition is selected from
water-insoluble polymer or wax.
__________
]11[]21[
‫תכשירים תוססים‬
]54[
FIZZY FORMULATIONS
]22[
]31[
]51[
]71[
20.03.1999
19814257.9
]32[ 31.03.1998
Int. Cl.7 A61K 009/00
VIATRIS GMBH & CO. KG,
GERMANY
WO/1999/049842
REINHOLD COHN AND PARTNERS,
21 AHAD HA'AM ST.
P.O.BOX 4060,
TEL AVIV 61040
]87[
]74[
138605
[57] Solid, rapidly disintegrating
administration forms for oral
administration in the form of effervescent
formulations which comprise selegiline or
its pharmaceutically acceptable salts as
active ingredient and an effervescent base
]33[
DE
,‫ריינהולד כהן ושותפיו‬
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
consisting of one or more alkaline earth
metal carbonates, an organic edible acid
and/or an alkali metal salt of citric acid
and, if appropriate, pharmaceutically
acceptable auxiliaries.
__________
1993
November 20, 2005– ‫י"ח בחשון התשס"ו‬
]11[]21[
]54[
TRANSDERMAL THERAPEUTIC
SYSTEM WHICH CONTAINS A
D2 AGONIST AND WHICH IS
PROVIDED FOR TREATING
PARKINSONISM AND A METHOD
FOR THE PRODUCTION
THEREOF
]22[
]31[
]51[
]71[
18.03.1999
19814084.3
]32[ 30.03.1998
Int. Cl.7 A61K 009/00, 009/70
LTS LOHMANN THERAPIESYSTEME AG, GERMANY
ADERIS PHARMACEUTICALS,
INC., U.S.A.
WO/1999/049852
DR. YITZHAK HESS & PARTNERS,
279 HAYARKON STREET
P.O.B. 6451
TEL AVIV 61063
]87[
]74[
[57] Transdermal therapeutical system
comprising a backing layer which is inert
to the ingredients of the matrix, a selfadhering matrix layer containing (-)5,6,7,8-tetrahydro-6-[propyl [2-(2-thienyl)
ethyl]amino]-1-naphthol, and a protective
layer which is to be removed before
application, characterized in that the
matrix layer
138722
‫מערכת רפואית טרנסדרמלית המכילה‬
‫ ואשר מסופקת עבור טיפול‬D2 ‫אגוניסט‬
‫במחלת הפרקינסון ושיטה עבור הייצור‬
‫של הנ"ל‬
]33[
DE
,‫ עו"פ‬,‫ד"ר יצחק הס ושותפיו‬
‫ תל אביב‬,6451 .‫ד‬.‫ ת‬, 279 ‫רחוב הירקון‬
(a) contains as a basis a non-aqueous
polymer adhesive based on acrylate or
silicone,
(b) has a solubility of ≥ 5% (per weight)
for the free base (-)-5,6,7,8-tetrahydro-6[propyl [2-(2-thienyl) ethyl]-amino]-1naphthol, and
(c) contains the free base (-)-5,6,7,8tetrahydro-6-[propyl [2-(2-thienyl)
ethyl]amino]-1-naphthol in an effective
amount.
__________
]11[]21[
November 20, 2005– ‫י"ח בחשון התשס"ו‬
138723
1994
]54[
COMPOSITION CONTAINING
CISPLATIN AND STILBENE FOR
TREATMENT OF TUMORS
]22[
]31[
29.03.1999
10-108708
]32[ 03.04.1998
19-229843
14.08.1998
Int. Cl.7 A61K 033/24
AJINOMOTO CO., INC., JAPAN
WO/1999/051246
DR. YITZHAK HESS & PARTNERS,
279 HAYARKON STREET
P.O.B. 6451
TEL AVIV 61063
]51[
]71[
]87[
]74[
‫תכשיר המכיל ציספלטין וסטילבן לטיפול‬
‫בגידולים ממאירים‬
]33[
JP
JP
,‫ עו"פ‬,‫ד"ר יצחק הס ושותפיו‬
‫ תל אביב‬,6451 .‫ד‬.‫ ת‬, 279 ‫רחוב הירקון‬
[57] An antitumor agent comprising a
stilbene derivative and a platinum
coordination compound, said agent
optionally containing one or more of
pharmaceutically acceptable carriers or
diluents, wherein said stilbene derivative is
at least one of compounds represented by
the following general formulae (1) and (2)
and pharmaceutically acceptable salts
thereof;
in which the compound may be in the form
of salt, hydrate, solvate or ester; in which
R1, R2 and R3 are independent from each
other and each denotes a lower alkoxy
group, R4, R5 and R6 are independent from
each other and each denotes any
substituent group of a hydrogen atom, a
halogen atom, a nitro group, a lower
alkoxy group, a phosphoric acid ester, a
phosphoric acid amide, an amino lower
alkoxy group, a lower alkyl amino lower
alkoxy group, a di-lower alkyl amino
lower alkoxy group, a mercapto group, a
lower alkyl thio group, an amino group, a
lower alkyl amino group, a di-lower alkyl
amino group, a lower alkyl group, an
amino lower alkyl group, a trifluoromethyl
group, a lower alkanoyl group, a lower
alkanoyl amino group and an amino acid
acylamino group, X denotes a hydrogen
atom or a nitrile group, and Het denotes a
heterocyclic ring.
__________
]11[]21[
1995
138761
November 20, 2005– ‫י"ח בחשון התשס"ו‬
]54[
METHOD AND SYSTEM FOR
EFFECTIVELY UTILIZING THE
SWITCHING CAPACITY OF
LOCAL EXCHANGES
]22[
]51[
]71[
]74[
28.09.2000
Int. Cl.7 H04L 012/56, H04Q 003/60
ECI TELECOM LTD.
ECI TELECOM LTD,
30 HASIVIM ST.
PETACH TIKVA 49517
[57] A method for supporting a changing
volume of a voice-grade traffic in an
access network having a local exchange
with a limited capacity, the method
comprising steps of: providing two or
more access networks, each having its
subscribers and its associated local
exchange with a limited capacity; each of
the access networks being capable of
dividing traffic, outgoing from its
subscribers, into the voice-grade traffic
portion and data traffic portion, and
capable of directing the data traffic portion
to a packet network while directing the
voice-grade traffic portion to a PSTN
network via said associated local
exchange; wherein the PSTN network and
the packet network are respectively
common for said two or more access
networks, defining an overload condition
November 20, 2005– ‫י"ח בחשון התשס"ו‬
‫שיטה ומערכת לניצול אפקטיבי של יכולת‬
‫המיתוג של מרכזיית טלפון‬
‫ פתח תקוה‬,‫ טלקום בע"מ‬.‫איי‬.‫סי‬.‫אי‬
,‫ טלקום בע"מ‬.‫ איי‬.‫ סי‬.‫אי‬
‫ פתח תקוה‬,30‫רחוב הסיבים‬
of a local exchange as a condition when
traffic there-through equals to a
predetermined threshold forming at least a
portion of the local exchange capacity;
defining a normal load condition of the
local exchange as a condition when traffic
there-through is below said predetermined
threshold, detecting the overload condition
on one of said local exchanges, the
overload local exchange being indicated
LE1; finding a remaining one of said local
exchanges being in the normal load
condition, the non-overload local exchange
being called LE2; partially diverting the
voice-grade traffic intended for the local
exchange LE1 and passing the diverted
voice-grade traffic to its destination via
said packet network and the local
exchange LE2, thereby reducing volume of
the voice-grade traffic via the LE1.
1996
__________
]11[]21[
]54[
TARGETED ADVERTISEMENT
USING TELEVISON DELIVERY
SYSTEMS
]22[
]31[
]51[
]71[
01.04.1999
054419
]32[ 03.04.1998
Int. Cl.7 H04N 007/173
SEDNA PATENT SERVICES, LLC.,
U.S.A.
WO/1999/052285
REINHOLD COHN AND
PARTNERS,
21 AHAD HA'AM ST.
P.O.BOX 4060,
TEL AVIV 61040
]87[
]74[
[57] A method for targeting
advertisements to a plurality of television
terminals, comprising: assigning at least
one primary advertisement to each of a
program channel; assigning at least one
alternate advertisement to at least one
1997
138805
‫פרסומות ממוקדות באמצעות מערכות‬
‫טלויויזיה‬
]33[
US
,‫ריינהולד כהן ושותפיו‬
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
feeder channel; and generating a switching
plan, wherein the switching plan instructs
each of the television terminals to select
one of the program channel and the at least
one feeder channel during a program break
occurring in a broadcast of a program on
November 20, 2005– ‫י"ח בחשון התשס"ו‬
the program channel, wherein generating
the switching plan comprises: assigning
each of the television terminals to at least
one group, designating a unique group
mask for each of the groups, and assigning
each of the groups to one of the program
channel and the at least one feeder
channel, wherein the group mask indicates
which of the television terminals tune to
the program channel and the at least one
feeder channel during the program break.
__________
]11[]21[
]54[
PROCESSING OF TEXTUAL
INFORMATION AND
AUTOMATED APPREHENSION
OF INFORMATION
]22[
]31[
]51[
]71[
11.02.1999
98109952.6
]32[ 02.06.1998
Int. Cl.7 G06F 017/28
INTERNATIONAL BUSINESS
MACHINES CORPORATION, U.S.A.
WO/1999/063455
SANFORD T.COLB & CO.,,
P.O.B. 2273,
REHOVOT 76122
]87[
]74[
138861
‫עיבוד מידע טקסטואלי מידע אוטומטית‬
]33[
EP
,'‫ קולב ושות‬.‫סנפורד ט‬
‫ רחובות‬,2273 .‫ד‬.‫ ת‬, ‫ מרמורק‬,4 ‫שער הגיא‬
[57] A method of processing textual
November 20, 2005– ‫י"ח בחשון התשס"ו‬
1998
information, comprising the steps of:
segmenting an input string which includes
textual information into segments; and
combining the segments with semantical
units from a knowledge database
representing a network of hierarchically
arranged semantical units which are
similar across hierarchies, the combining
step generating a resulting semantic
network of hierarchically arranged
semantical units which are similar across
hierarchies.
__________
]11[]21[
]54[
MULTIPLE WAVEFORM
SOFTWARE RADIO
]22[
]31[
]51[
]71[
]87[
]74[
27.05.1999
086804
]32[ 29.05.1998
Int. Cl.7 H04B 001/38
MOTOROLA, INC., U.S.A.
WO/1999/062194
REINHOLD COHN AND
PARTNERS,
21 AHAD HA'AM ST.
P.O.BOX 4060,
TEL AVIV 61040
[57] A transceiver comprising: a
transmitter comprising: an information
receiving input receiving input digital
information; an rf up-converter operatable
over a plurality of waveforms; and one or
more processor means disposed between
said input and said rf up-converter for
operating in accordance with a plurality of
1999
138931
‫תוכנת רדיו בעלת צורת גלים רבות‬
]33[
US
,‫ריינהולד כהן ושותפיו‬
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
predetermined first waveform software
each first waveform software being
associated with a corresponding one of a
plurality of first waveforms such that said
digital information is processed in
accordance with selected ones of said
plurality of predetermined first waveform
software to produce digital output
November 20, 2005– ‫י"ח בחשון התשס"ו‬
information representative of said input
digital information for said rf up converter
whereby one or more first waveforms of
said plurality of first waveforms is
produced; a receiver comprising: a second
waveform receiving input receiving one or
more of a plurality of second waveforms;
an rf down-converter coupled to said
second waveform receiving input and
operable over a plurality of second
waveforms to produce received digital
output information; an output; and said one
or more second processor means being
operable in accordance with a plurality of
predetermined second waveform software;
each said second waveform software being
associated with a corresponding one
second waveform of a plurality of second
waveforms such that said received digital
information is processed in accordance
with selected ones of said plurality of
predetermined second waveform software
to produce received digital output
information at said output; a first memory
having stored therein said plurality of
predetermined first waveform software; a
second memory for receiving one or more
first waveform software of said plurality of
first waveform software for a
corresponding number of selected ones of
said plurality of first waveforms; said
second memory receiving said one or more
first waveform software from said first
memory; and said second memory being
coupled to said one or more processor
means to provide said selected ones of said
predetermined first waveform software to
said one or more processor means; a third
memory having stored therein said
plurality of predetermined second
waveform software; a fourth memory for
receiving one or more second waveform
software of said plurality of second
waveform software for a corresponding
number of selected ones of said plurality of
second waveforms, said second memory
receiving said one or more second
waveform software from said third
memory; and said fourth memory being
coupled to said one or more processor
means to provide said selected ones of said
predetermined second waveform software
to said one or more processor means.
__________
]11[]21[
November 20, 2005– ‫י"ח בחשון התשס"ו‬
139003
2000
]54[
POSITIVE LOCK COUPLING
]22[
]31[
]51[
]71[
14.04.1999
09/070230
]32[ 30.04.1998
Int. Cl.7 F16L 019/00
STANLEY AVIATION
CORPORATION, U.S.A.
WO/1999/057476
REINHOLD COHN AND PARTNERS,
21 AHAD HA'AM ST.
P.O.BOX 4060,
TEL AVIV 61040
]87[
]74[
[57] A threaded coupling apparatus (10)
for interconnecting ends of first and
second fluid-carrying conduit members
(11, 12) in a fixed releasable locking
relationship which includes first and
second coupling members (34, 25)
circumferentially engageable with the ends
of the conduit members to hold them in
fluid communication, said coupling
members each having annular outer
surfaces and being rotatable with respect to
each other in a locking direction to a
locked position and rotatable in an
opposite unlocking direction to an
unlocked position, said second coupling
member having a peripheral groove (46) in
said annular outer surface thereof and a
first peripheral facing surface (75) located
on said first coupling member, the
improvement comprising: a lock ring (40)
located on said second coupling member ,
said lock ring having an annular wall
forming a second peripheral facing surface
(56) which faces said first peripheral
facing surface and an internal peripheral
retaining groove (54); a complementary
locking tab (76) located on said first
peripheral facing surface; a
complementary locking slot (64) located
on said second peripheral facing surface
configured for locking engagement with
said complementary locking tab; first and
second cooperating elements (32, 38) on
said first and second coupling members,
2001
‫מחבר נעילה‬
]33[
US
,‫ריינהולד כהן ושותפיו‬
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
respectively, for moving said first and
second peripheral facing surfaces toward
each other when said coupling members
are rotated in the locking direction; an
annular spring (42) mounted within said
internal peripheral retaining groove of said
lock ring, said annular spring having an
inner peripheral edge with a plurality of
peripherally spaced spring tabs extending
therefrom and received in said peripheral
retaining groove of said second coupling
member, said annular spring urging said
second peripheral facing surface of said
lock ring toward said first peripheral
facing surface of said first coupling
member so that said complementary
locking tab and complementary locking
slot become aligned and subsequently
engage with each other in a fixed and
locked position; a longitudinally extending
first keyway, having a first width, formed
in said annular outer surface of said second
coupling member which intersects said
peripheral retaining groove; a spring key
(50) of substantially said first width
located on said inner peripheral edge of
said annular spring which is placed in said
first keyway to angularly orient said
annular spring with said second coupling
member; a first lock ring key (68) of
substantially said first width extending
from said inner peripheral edge of said
annular wall of said lock ring positioned in
said first keyway to angularly orient said
lock ring with said second coupling
November 20, 2005– ‫י"ח בחשון התשס"ו‬
member and said annular spring, a
longitudinally extending second keyway
(71), having a second width, formed in
said annular outer surface of said second
coupling member, angularly spaced from
said first keyway, and intersecting said
peripheral retaining groove; and a second
lock ring key (70) of substantially said
second width extending from said inner
peripheral edge of said annular wall of said
lock ring, angularly spaced from said first
lock ring key a distance equal to the
angular spacing of said first and second
keyways and positioned in said second
keyway.
__________
November 20, 2005– ‫י"ח בחשון התשס"ו‬
2002
]11[]21[
]54[
LIGHTWEIGHT POSITIVE LOCK
COUPLING
]22[
]31[
]51[
]71[
14.04.1999
070229
]32[ 30.04.1998
Int. Cl.7 F16L 019/00
STANLEY AVIATION
CORPORATION, U.S.A.
WO/1999/057477
REINHOLD COHN AND
PARTNERS,
21 AHAD HA'AM ST.
P.O.BOX 4060,
TEL AVIV 61040
]87[
]74[
[57] A threaded coupling apparatus (10)
for interconnected ends of first and second
fluid-carrying conduit members (11, 12) in
a fixed releasable locking relationship
which includes first and second coupling
members (25, 36), each having a
peripheral surface, circumferentially
engageable with the ends of the conduit
members to hold them in fluid
communication, said coupling members
being rotatable with respect to each other
in a locking direction to a locked position
and in an opposite unlocking direction to
an unlocked position to unfasten said
coupling apparatus, the improvement
comprising: a lock ring (43) mounted
about said peripheral surface of said first
coupling member; at least one
complementary locking recess (58) located
on said lock ring; at least one
complementary locking tab (68) located on
said second coupling member; external
threads (34) on said first coupling member,
said external threads forming alternating
ridges and valleys, said ridges having a
2003
139004
‫מחבר נעילה‬
]33[
US
,‫ריינהולד כהן ושותפיו‬
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
first larger diameter and said valleys
having a second smaller diameter; internal
threads (42) on said second coupling
member for cooperative engagement with
said external threads, said threads being
angularly oriented with said at least one
locking recess and said at least one locking
tab so that they become aligned only when
said coupling members are rotated with
respect to each other to said locked
position; and an annular resilient member
(44) having an internal peripheral edge
having a diameter which is lesser than said
first larger diameter mounted within and
supporting said lock ring and positioned on
said first coupling member for urging said
at least one locking recess toward said at
least one locking tab so that they make
contact with each other and subsequently
interlock during rotation in the locking
direction when said at least one locking
recess and said at least one locking tab
become aligned to hold said first and
second coupling members in a fixed
rotational and locked position.
November 20, 2005– ‫י"ח בחשון התשס"ו‬
__________
]11[]21[
139130
)‫בנזיל‬-(‫אמינואתוקסי‬-2)-4} -1-‫פניל‬-2
‫אינדול בתערובת עם אסטרוגנים‬
]54[
2-PHENYL-1 {4-(2AMINOETHOXY)- BENZYL} INDOLE IN COMBINATION WITH
ESTROGENS
]22[
]31[
]51[
11.05.1999
079561
]32[ 15.05.1998
]33[ US
Int. Cl.7 A61K 031/40, 031/565, A61P 005/00, 009/00, C07D 209/08, 209/10, 401/12,
403/12, 405/12
WYETH, U.S.A.
WO/1999/059581
REINHOLD COHN AND
,‫ריינהולד כהן ושותפיו‬
PARTNERS,
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
21 AHAD HA'AM ST.
P.O.BOX 4060,
TEL AVIV 61040
]71[
]87[
]74[
November 20, 2005– ‫י"ח בחשון התשס"ו‬
2004
[57] A pharmaceutical composition
comprising one or more estrogens and a
compound having the structure:
wherein: R1 is selected from H, OH or the
C1-C12 esters (straight chain or branched)
or C1-C12 (straight chain or branched or
cyclic) alkyl ethers thereof, or halogens; or
C1-C4 halogenated ethers including
trifluoromethyl ether and trichloromethyl
ether,
R2, R3, R4, R5, and R6 are independently
selected from H, OH or the C1-C12 esters
(straight chain or branched) or C1-C12
alkyl ethers (straight chain or branched or
cyclic) thereof, halogens, or C1-C4
halogenated ethers including
trifluoromethyl ether and trichloromethyl
ether, cyano, C1-C6 alkyl (straight chain or
branched), or trifluoromethyl, with the
proviso that, when R1 is H, R2 is not OH,
X is selected from H, C1-C6 alkyl, cyano,
nitro, trifluoromethyl, halogen;
n is 2 or 3;
Y is selected from:
(a) the moiety;
wherein R7 and R8 are independently
selected from H, C1-C6 alkyl, or phenyl
optionally substituted by CN, C1-C6 alkyl
(straight chain or branched), C1-C6 alkoxy
(straight chain or branched), halogen, -OH,
-CF3 or –OCF3; or R7 and R8 are
concatenated together as –(CH2)p-, wherein
p is an integer of from 2 to 6, preferably 4
to 6, the ring so formed is optionally
substituted with 1-3 substituents selected
from C1-C3 alkyl, trifluoromethyl, halogen,
hydrogen, phenyl, nitro and –CN
(b) a five-, six- or seven- membered
saturated, unsaturated or partially
unsaturated heterocycle containing up to
two heteroatoms selected from –O-, -NH-,
N(C1-C4 alkyl)-, N= and –S(O)m-, wherein
m is an integer of from 0-2 optionally
substituted with 1-3 substituents
independently selected from hydroxyl,
halo, C1-C4 alkyl, trihalomethyl, C1-C4
alkoxy, trihalomethoxy, C1-C4 acyloxy, C1C4 alkylthio, C1-C4 alkylsulfinyl, C1-C4
alkylsulfonyl, hydroxyl (C1-C4) alkyl, CO2H, -CN, -CONHR1-, -NH2 C1-C4
alkylamino, di-( C1-C4) alkylamino, NHSO2R1, -NHCOR1-, -NO2, and phenyl
optionally substituted with 1-3 (C1-C4)
2005
November 20, 2005– ‫י"ח בחשון התשס"ו‬
alkyl, wherein R1 is as defined above or
C1-C6 alkyl;
(c) a bicyclic heterocycle containing from
6-12 carbon atoms either bridged or fused
and containing up to two heteroatoms
selected from –O-, -NH-, -N(C1-C4 alkyl)-,
and –S(O)m-, wherein m is an integer of
from 0-2, optionally substituted with 1-3
substituents independently selected
hydroxyl, halo, C1-C4 alkyl, trihalomethyl,
C1-C4 alkoxy, trihalomethoxy, C1-C4
acyloxy, C1-C4 alkylthio, C1-C4
alkylsulfinyl, C1-C4 alkylsulfonyl,
hydroxyl (C1-C4) alkyl, -CO2H, -CN-, CONHR1-, -NH2 C1-C4 alkylamino, di(C1C4) alkylamino, -NHSO2R1, -NHCOR1, NO2-, and phenyl optionally substituted
with 1-3 (C1-C4) alkyl; or a
pharmaceutically acceptable salt thereof,
and a pharmaceutically acceptable carrier
or excipient.
__________
]11[]21[
139141
B12 1,2,6,7,8 -‫פתלאימידו‬--7 ‫ביניים‬-‫חומרי‬
-‫] בנזאזפין‬A - 1,2[ ]2[ ‫פיריד‬-‫הקסאהידרו‬‫און ואנאלוגים שלהם להכנת מעכבים‬-6
‫וטטראציקליים לאנקפאלינז ולאנזים‬-‫טרי‬
‫הממיר אנגיוטנזין‬
]54[
7-PHTHALIMIDO-1,2,6,7,8,12B
HEXAHYDRO-PYRIDO [2,1A]BENZAZEPIN-6- ONE AND
ANALOGS THEREOF
INTERMEDIATES FOR
PREPARING TRI-AND
TETRACYCLIC INHIBITORS OF
ENKEPHALINASE AND
ANGIOTENSIN CONVERTING
ENZYME
]22[
]31[
18.12.1995
360915
]32[ 21.12.1994
]33[ US
535403
24.10.1995
US
Int. Cl.7 C07D 401/10, 401/14, 405/14, 409/14, 471/04, 471/14, 491/147, 495/14
DIVISION FROM 116428
AVENTIS PHARMACEUTICALS
INC., U.S.A.
EITAN, PEARL, LATZER AND
,‫ לצר וכהן צדק‬,‫ פרל‬,‫איתן‬
COHEN ZEDEK,
‫ הרצליה‬,12688 .‫ד‬.‫ ת‬, 7 ‫רחוב שנקר‬
P.O.B. 12688
HERZLIYA 46733
]51[
]62[
]71[
]74[
[57] A compound of the formula
November 20, 2005– ‫י"ח בחשון התשס"ו‬
2006
wherein G completes an aromatic ring
selected from the group consisting of
wherein X1 is selected from the group
consisting of S and NH;
X2 is selected from the group consisting of
S, O, and NH; and
R is selected from the group consisting of
hydrogen, hydroxyl, phenyl , and C1-C4
alkoxy.
__________
]11[]21[
]54[
PHARMACEUTICAL
COMPOSITION CONTAINING A
MACROLIDE COMPOUND
]22[
]31[
]51[
]71[
26.04.1999
10-117271
]32[ 27.04.1998
Int. Cl.7 A61K 031/40, A61P 017/00
FUJISAWA PHARMACEUTICAL
CO., LTD., JAPAN
WO/1999/055332
WOLFF, BREGMAN AND GOLLER,
KEREN HAYESOD ST 19B,
P.O.B. 1352
JERUSALEM 91013
]87[
]74[
[57] A pharmaceutical composition in a
gel form, which consists essentially of a
tricyclic compound, a
dissolution/absorption promoter, a
2007
139210
‫תכשיר רוקחות המכיל תרכובות‬
‫מקרולידית‬
]33[
JP
,‫ ברגמן וגולר‬,‫וולף‬
‫ ירושלים‬,1352 .‫ד‬.‫ ת‬, '‫ב‬19 ‫רחוב קרן היסוד‬
pharmaceutical base, a compatibilizing
agent and a thickener, wherein said
tricyclic compound is the compound of the
formula
November 20, 2005– ‫י"ח בחשון התשס"ו‬
(wherein each of adjacent pairs of R1 and
R2, R3 and R4, R5 and R6 independently
(a) is two adjacent hydrogen atoms, but R2
may also be an alkyl group or,
(b) may form another bond formed
between the carbon atoms to which they
are attached;
R7 is a hydrogen atom, a hydroxyl group, a
protected hydroxyl group, or an alkoxy
group, or an oxo group together with R1;
R8 and R9 are independently a hydrogen
atom or a hydroxyl group;
R10 is a hydrogen atom, an alkyl group, an
alkyl group substituted by one or more
hydroxyl groups, an alkenyl group, an
alkenyl group substituted by one or more
hydroxyl groups, or an alkyl group
substituted by an oxo group;
X is an oxo group, (a hydrogen atom) or a
group represented by the formula
-CH2O-;
Y is an oxo group, (a hydrogen atom, and a
hydroxyl group), (a hydrogen atom and a
hydrogen atom), or a group represented by
the formula -N-NR11R12 or N-OR13;
R11 and R12 are independently a hydrogen
atom, an alkyl group, an aryl group or a
tosyl group;
R13, R14, R15, R16, R17, R18, R19, R22 and R23
are independently a hydrogen atom or an
alkyl group;
R24 is an optionally substituted ring system
which may contain one or more
heteroatoms;
n is an integer of 1 or 2; and in addition to
the above definitions, Y, R10 and R23,
together with the carbon atoms to which
they are attached, may represent a
saturated or unsaturated 5- or 6-membered
nitrogen, sulfur and/or oxygen containing
heterocyclic ring optionally substituted by
one or more groups selected from the
group consisting of an alkyl, a hydroxyl,
an alkoxy, a benzyl, a group of the formula
–CH2Se(C6H5), and an alkyl substituted by
one or more hydroxyl groups; the
dissolution/absorption promoter is diethyl
sebacate; the pharmaceutical base is a
hydrophilic glycol, the compatibilizing
agent is diethylene glycol monoethyl ether;
and the thickener is cellulose polymer or
carboxyvinyl polymer, in which the
amount of the dissolution/absorption
promoter and the compatibilizing agent in
the total composition is about 1-20%
(w/w) and about 5-15% (w/w),
respectively.
__________
November 20, 2005– ‫י"ח בחשון התשס"ו‬
2008